Results 71 to 80 of about 109,209 (296)

Deciphering transcriptional plasticity in pancreatic ductal adenocarcinoma reveals alterations in sensory neuron innervation

open access: yesMolecular Oncology, EarlyView.
Pancreatic sensory neurons innervating healthy and PDAC tissue were retrogradely labeled and profiled by single‐cell RNA sequencing. Tumor‐associated innervation showed a dominant neurofilament‐positive subtype, altered mitochondrial gene signatures, and reduced non‐peptidergic neurons.
Elena Genova   +14 more
wiley   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

open access: yesMolecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh   +12 more
wiley   +1 more source

MultiCycPermea: accurate and interpretable prediction of cyclic peptide permeability using a multimodal image-sequence model

open access: yesBMC Biology
Background Cyclic peptides, known for their high binding affinity and low toxicity, show potential as innovative drugs for targeting “undruggable” proteins. However, their therapeutic efficacy is often hindered by poor membrane permeability.
Zixu Wang   +7 more
doaj   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau   +8 more
wiley   +1 more source

Isolating cyclic peptides from linear peptides

open access: yes, 2023
Poster and abstract presented at the FYRE in STEM Showcase, 2023.Research project completed at the Department of Chemistry and Biochemistry.For decades, medicines treating ailments from autoimmune diseases to fungal infections have included peptides ...
Mandapaka, Hyma   +2 more
core  

Computational prediction of plasma protein binding of cyclic peptides from small molecule experimental data using sparse modeling techniques

open access: yesBMC Bioinformatics, 2018
Background Cyclic peptide-based drug discovery is attracting increasing interest owing to its potential to avoid target protein depletion. In drug discovery, it is important to maintain the biostability of a drug within the proper range.
Takashi Tajimi   +5 more
doaj   +1 more source

Sweetening Cyclic Peptide Libraries [PDF]

open access: yesChemInform, 2004
AbstractFor Abstract see ChemInform Abstract in Full Text.
openaire   +2 more sources

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Fluorescence resonance energy transfer (FRET) peptides and cycloretro-inverso peptides derived from bradykinin as substrates and inhibitors of prolyl oligopeptidase

open access: yes, 2007
Prolyl oligopeptidase (POP, EC 3.4.21.26) is a member of a family of serine peptidases with post-proline cleaving activity towards peptides. It is located in the cytosol in active form but without hydrolytic activity on proteins or peptides higher than ...
Melo, Robson L.   +15 more
core   +1 more source

Binding Interactions of Peptide Aptamers

open access: yesMolecules, 2020
Peptide aptamers are short amino acid chains that are capable of binding specifically to ligands in the same way as their much larger counterparts, antibodies. Ligands of therapeutic interest that can be targeted are other peptide chains or loops located
Roger R. C. New   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy